Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$18.9 million.

  • Foghorn Therapeutics' Cash from Operations rose 1021.19% to -$18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.3 million, marking a year-over-year increase of 1458.12%. This contributed to the annual value of -$100.4 million for FY2024, which is 1498.65% up from last year.
  • According to the latest figures from Q3 2025, Foghorn Therapeutics' Cash from Operations is -$18.9 million, which was up 1021.19% from -$21.0 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Cash from Operations ranged from a high of $271.5 million in Q1 2022 and a low of -$32.2 million during Q2 2023
  • In the last 5 years, Foghorn Therapeutics' Cash from Operations had a median value of -$24.0 million in 2025 and averaged -$7.3 million.
  • Per our database at Business Quant, Foghorn Therapeutics' Cash from Operations crashed by 85209.1% in 2021 and then surged by 127308.51% in 2022.
  • Over the past 5 years, Foghorn Therapeutics' Cash from Operations (Quarter) stood at $11.9 million in 2021, then plummeted by 343.43% to -$28.9 million in 2022, then rose by 4.78% to -$27.5 million in 2023, then increased by 10.97% to -$24.5 million in 2024, then rose by 23.08% to -$18.9 million in 2025.
  • Its last three reported values are -$18.9 million in Q3 2025, -$21.0 million for Q2 2025, and -$24.0 million during Q1 2025.